Lipoprotein(a) and Non-Lp(a) ApoB: Differential Atherogenicity per Particle in the ODYSSEY OUTCOMES Trial

This post-hoc analysis of ODYSSEY OUTCOMES — a landmark RCT of alirocumab versus placebo in 18,924 post-ACS patients — examined the comparative per-particle atherogenicity of Lp(a)-associated ApoB versus non-Lp(a) ApoB, using the trial’s randomization as a natural experiment that differentially reduced both fractions.

Alirocumab reduced both LDL-C and Lp(a), allowing investigators to partition the total ApoB reduction into Lp(a) ApoB and non-Lp(a) ApoB components and estimate the cardiovascular risk reduction attributable to each. Lp(a) ApoB particles were found to be substantially more atherogenic per particle than non-Lp(a) ApoB particles — by a factor estimated at approximately 6-fold — consistent with the mechanistic understanding that Lp(a) carries oxidized phospholipid cargo that makes individual particles more inflammatory and more potent drivers of plaque progression and thrombosis.

This analysis provides quantitative evidence for a fundamental distinction in the CAD risk landscape: not all ApoB particles are equally dangerous. The Lp(a) fraction — while representing a small numerical fraction of total ApoB in most patients — exerts disproportionate atherogenic influence per particle. For patients with elevated Lp(a), standard ApoB reduction strategies targeting non-Lp(a) LDL may leave the most dangerous particle fraction underaddressed.

This has direct implications for treatment strategy: in patients with both elevated LDL-C and elevated Lp(a), achieving standard LDL-C or ApoB targets may still leave a high-risk Lp(a) burden that requires dedicated targeting.

We rate the evidence strong. A large post-hoc RCT analysis in 18,924 patients formally quantifying Lp(a) ApoB’s approximately 6-fold greater per-particle atherogenicity versus non-Lp(a) ApoB — foundational evidence for prioritizing Lp(a)-specific risk assessment and treatment in high-risk patients.